Trial record 3 of 23 for: cancer | First posted from 04/21/2016 to 04/21/2016
Pharmacist's Influence on Breast Cancer Patient Quality of Life (PIBC)
|ClinicalTrials.gov Identifier: NCT02746666|
Recruitment Status : Completed
First Posted : April 21, 2016
Last Update Posted : October 27, 2016
University Hospital "Sestre Milosrdnice"
Information provided by (Responsible Party):
Robert Šeparović, University Hospital "Sestre Milosrdnice"
The purpose of this study is to investigate the impact of pharmacist behavioral intervention's influence on breast cancer patients' quality of life. Croatian randomized controlled trial. Targeted population: general population of breast cancer patients under the first adjuvant anthracycline chemotherapy. Primary outcome: difference in EORTC QLQ-BR23 questionnaire result from the baseline to after 3 week cycle.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer, Quality of Life||Behavioral: Pharmacist's behavioral intervention||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||70 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Influence of a Clinical Pharmacist's Intervention on Quality of Life of a Breast Cancer Patient Under Adjuvant Chemotherapy|
|Study Start Date :||April 2016|
|Actual Primary Completion Date :||June 2016|
|Actual Study Completion Date :||June 2016|
Under pharmacist's behavioral intervention
Behavioral: Pharmacist's behavioral intervention
Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
No Intervention: Control
No pharmacist's behavioral intervention
Primary Outcome Measures :
- changes in quality of life of a breast cancer patient under chemotherapy, after a clinical pharmacist's behavioral intervention, measured by EORTC B23 questionnaire [ Time Frame: up to two months ]
No Contacts or Locations Provided